Therapy of the drug requires careful monitoring by personnel with the appropriate qualifications and having the necessary equipment at their disposal. Prescribe a drug or make changes in immunosuppressive therapy can only doctors with experience of immunosuppressive therapy in patients with transplanted organs.
The uncontrolled transfer of patients from one drug tacrolimus to another (including the transition from conventional capsules to prolonged capsules) is unsafe.This can lead to rejection of the transplant or an increase in the incidence of side effects, including hypo- or hyperimmunosuppression due to the appearance of clinically significant differences in the exposure of tacrolimus. The patient should take one of the dosage forms of tacrolimus in accordance with the recommended dosage regimen.
The change in dosage form or dosage regimen should be carried out only under the supervision of a specialist in the field of transplantology. After the transfer, it is necessary to carefully monitor the concentration of tacrolimus in the blood and adjust the dose of the drug to maintain the systemic exposure of tacrolimus at an adequate level.
If you miss Tacrolimus capsules, take the next dose in time. A double dose of the drug should not be taken.
The initial doses presented below should only be considered as recommendations. In the initial postoperative period Tacrolimus usually used in combination with other immunosuppressants. The dose may vary depending on the regimen of immunosuppressive therapy.The choice of the dose of the drug should be based, first of all, on the clinical evaluation of the risk of rejection and individual drug tolerance, as well as on the monitoring of tacrolimus concentration in the blood.
When there are clinical signs of rejection, consideration should be given to the need for correcting the regimen of immunosuppressive therapy.
In most cases Tacrolimus in the form of capsules is administered orally. Children up to 3 years of the drug should be taken, after opening the capsule and mixing its contents with water. If necessary, the contents of the capsules can be mixed with water and injected through a nasogastric tube.
The daily dose of the drug is divided into 2 doses (in the morning and in the evening) in equal doses. Capsules should be taken immediately after they are removed from the blister.
Capsules are washed down with a liquid, preferably water. To achieve maximum absorption, capsules should be taken on an empty stomach, 1 hour or 2-3 hours after eating.
To prevent rejection of the graft, the state of immunosuppression must be maintained at all times, hence the duration of therapy is not limited.
Liver transplantation
Prevention of graft rejection
Adults
Oral capsule therapy Tacrolimus it is necessary to start with a dose of 0.10-0.20 mg / kg / day, divided into two doses (for example, in the morning and in the evening). If the patient's condition allows taking the capsules inside, the drug should be started approximately 12 hours after the operation is completed.
If the patient's condition does not allow the medication to be taken orally, intravenous therapy should be started in the form of a solution for infusions at a dose of 0.01-0.05 mg / kg / day as a continuous 24-hour infusion.
Children
The initial dose of 0.30 mg / kg / day of the drug should be divided into two doses (for example, in the morning and in the evening). If the patient's clinical condition does not allow him to take the medicine inside, intravenous therapy should be started in the form of a solution for infusions at a dose of 0.05 mg / kg / day as a continuous 24-hour infusion.
Supportive therapy
Adults and children
In the posttransplant period, the doses of the drug are usually reduced. In some cases, it is possible to cancel preparations of concomitant immunosuppressive therapy, leaving Tacrolimus as a monotherapy.When the patient's condition improves after transplantation, the pharmacokinetics of tacrolimus may change, a dose adjustment may be required.
Treatment of rejection
Adults and children
To treat episodes of rejection, it is necessary to use higher doses of the drug in combination with additional glucocorticosteroid therapy and short courses of mono / polyclonal antibodies. If signs of toxicity are noted, a dose reduction may be required.
When transferring patients to capsule therapy Tacrolimus the same initial doses are recommended, as with primary immunosuppression. Information on the transfer of patients with cyclosporine therapy on Tacrolimus is given at the end of the section "Correction of the dose of the drug in special patient populations."
Kidney Transplantation
Prevention of rejection
Adults
Oral capsule therapy should be started at a dose of 0.20-0.30 mg / kg / day, divided into two divided doses (eg, in the morning and in the evening). The drug should be started within 24 hours after the operation is completed. If the patient's condition does not allow taking the medication internally, intravenous therapy should be started from a dose of 0.05-0.10 mg / kg / day as a continuous 24-hour infusion.
Children
The initial dose of 0.30 mg / kg / day of the drug Tacrolimus should be divided into two doses (for example, in the morning and in the evening). If the patient's clinical condition does not allow him to take the drug inside, intravenous therapy should be started at a dose of 0.075-0.100 mg / kg / day as an intravenous infusion within 24 hours.
Supportive therapy
Adults and children
In the course of maintenance therapy, the doses of the drug are usually reduced. In some cases, it is possible to cancel concomitant immunosuppressants, leaving Tacrolimus as a basic component of dual therapy. If the patient's condition improves after transplantation, the pharmacokinetics of tacrolimus may change, a dose adjustment may be required.
Treatment of rejection reaction
Adults and children
To treat episodes of rejection, it is necessary to use higher doses of the drug in combination with additional glucocorticosteroid therapy and short courses of mono / polyclonal antibodies. If signs of toxicity are noted, a dose reduction may be required.
When transferring patients to capsule therapy Tacrolimus the same initial doses are recommended, as with primary immunosuppression.Information on the transfer of patients with cyclosporine therapy on Tacrolimus is given at the end of the section "Correction of the dose of the drug in special patient populations."
Heart transplantation
Prevention of rejection
Adults
Tacrolimus can be used in combination with induction therapy with antibodies (which allows delaying the onset of the drug) or without antibodies clinically stable patients. Following the induction of antibodies, oral capsule therapy should be started at a dose of 0.075 mg / kg / day divided into two doses (eg, morning and evening), within 5 days after surgery, once the patient's clinical condition is stabilized. If the patient's condition does not allow taking the drug inside, it is necessary to start intravenous therapy at a dose of 0.01-0.02 mg / kg / day as a continuous 24-hour infusion.
There is an alternative approach in which oral administration of tacrolimus begins within 12 hours after transplantation. This approach is intended for patients without signs of impaired function of internal organs (eg, kidneys). In this case tacrolimus in an initial dose of 2-4 mg / day is combined with mycophenolate mofetil and glucocorticosteroids, or sirolimus and glucocorticosteroids.
Children
After heart transplantation in children, primary immunosuppression with the drug Tacrolimus can be carried out both in combination with induction by antibodies, and independently. In those cases when induction is not carried out with antibodies and tacrolimus is administered intravenously, the recommended initial dose is 0.03-0.05 mg / kg / day as a continuous 24-hour infusion until the tacrolimus concentration in whole blood reaches 15-25 ng / ml. At the first clinical opportunity, the patient should be transferred to the oral administration of the drug. The initial oral dose should be 0.30 mg / kg / day and administered through 8-12 hours after discontinuation of intravenous infusion.
Following the induction of antibodies, oral capsules should be started at a dose of 0.10-0.30 mg / kg / day, divided into two doses (for example, in the morning and in the evening).
Supportive therapy
Adults and children
In the course of maintenance therapy, the doses of the drug are usually reduced. Improvement of the patient's condition after transplantation can change the pharmacokinetics of tacrolimus, and there will be a need for correction of the dose of the drug.
Treatment of rejection reaction
Adults and children
To treat episodes of rejection, it is necessary to use the drug Tacrolimus in higher doses in combination with additional glucocorticosteroid therapy and short courses of mono / polyclonal antibodies.
When transferring patients to capsule therapy Tacrolimus the initial daily dose for adults is 0.15 mg / kg / day, for children 0.2-0.3 mg / kg / day should be divided into two doses (for example, in the morning and in the evening).
Information on the transfer of patients with cyclosporine therapy Tacrolimus is given at the end of the section "Correction of the dose of the drug in special patient populations."
Recommended doses for treatment of rejection after allotransplantation of other organs
Recommendations for dosing the drug Tacrolimus for patients after lung, pancreas and small intestine allotransplantation are based on data from selected prospective clinical studies.
After transplantation lung Tacrolimus is used in the initial dose of 0.10-0.15 mg / kg / day.
After allotransplantation pancreas the initial dose is 0.20 mg / kg / day.
After allotransplantation small intestine the initial dose of the drug is 0.3 mg / kg / day.
Correction of dose of the drug in special populations of patients
Patients with hepatic insufficiency
Patients with severe hepatic impairment may require a dose reduction in order to maintain the target minimum concentration of the drug within the recommended values.
Patients with renal insufficiency
Since the pharmacokinetics of tacrolimus does not change with renal function, no dose adjustment is required. However, due to the presence of nephrotoxic action in tacrolimus, it is recommended to carefully monitor the kidney function (including serum creatinine concentration, creatinine clearance and diuresis level).
Children
To achieve similar concentrations of the drug in the blood, children usually require doses that are 1.5-2 times higher than doses for adults.
Elderly patients
Currently, there is no evidence of the need to adjust the dose of the drug for elderly patients.
Transfer from cyclosporine to drug treatment Tacrolimus
Simultaneous use of drugs of cyclosporine and tacrolimus may increase the half-life of cyclosporine and enhance toxic effects.Therefore, care must be taken when transferring patients from cyclosporine to tacrolimus therapy. Capsule treatment Tacrolimus should be started after an assessment of the concentrations of cyclosporine in the blood and the clinical state of the patient. Go to Tacrolimus should be postponed in the presence of elevated concentrations of cyclosporine in the patient's blood. Practice shows that Tacrolimus appoint 12-24 hours after the abolition of cyclosporine. After the transfer of the patient, it is necessary to continue monitoring the concentrations of cyclosporine in the patient's blood in connection with the possibility of impaired clearance of cyclosporine.
Recommendations for monitoring the therapeutic concentration of tacrolimus in the blood
Dose choice Tacrolimus is based on clinical assessment of rejection and drug tolerability in each individual patient. To optimize dosing, tacrolimus concentration in whole blood is measured using immune methods, including semi-automatic enzyme-linked immunosorbent assay (MIFA). A comparison of data on the concentration of tacrolimus in the blood, published in the literature,with individual clinical indicators should be conducted with caution and based on knowledge and understanding of the valuation method used.
In the postoperative period, it is important to monitor the minimum concentrations of tacrolimus in whole blood. To determine the minimum concentrations of tacrolimus in the blood, it is necessary to obtain blood samples 12 hours after taking the drug, immediately before the next dose. The frequency of tacrolimus concentration in the blood should depend on clinical needs. As tacrolimus is a drug with a low clearance value, after adjusting the dose, the time to reach the equilibrium minimum concentration of tacrolimus in the blood can be several days. The minimum concentration of tacrolimus in the blood should be monitored approximately twice per week during the early post-transplant period and then periodically during maintenance therapy. The minimum concentration of tacrolimus in the blood should also be monitored after changing the dose of the drug Tacrolimus, the regime of immunosuppression or after joint application with drugs that affect the concentration of tacrolimus in whole blood.
The results of clinical studies indicate that the treatment with capsules Tacrolimus is most successful in those cases when the minimum concentration of tacrolimus in the blood does not exceed 20 ng / ml. Interpreting concensus datatracings of tacrolimus in whole blood, it is important to assess the clinical state of the patient.
In clinical practice, in the early post-transplant period, the minimum concentration of tacrolimus in whole blood usually varies between 5-20 ng / ml after liver transplantation and 10-20 ng / ml after kidney and heart transplantation. Later, during maintenance therapy after liver, kidney and heart transplantation, tacrolimus concentrations in the blood range from 5 to 15 ng / ml.